In addition, 2 of the 3 patients with a partial response in the main Q2W dose-escalation cohort (13) had strong expression of CEACAM5 (intensity ≥2+ in 100% of tumor cells), whereas 17 of 43 (40%) patients in the current study had CEACAM5 expression of intensity ≥2+ in ≥80% of tumor cells. Here, CEACAM5 is linked to neoplasm.